Stockreport

ImmunityBio commences CD19 t-haNK cell therapy trial for NHL [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF therapy for the treatment of non-Hodgkin's lymphoma (NHL), with the dosing of the first patients. The CD19-t-haNK cell therapy uses a stable clonal NK cell line derive [Read more]